Is visual field constriction in epilepsy patients treated with vigabatrin reversible?

Journal of Neurology

Volumn 249, Issue 8, 2002, Pages 1066-1071

  Schmidt, T ^a   Ruther K ^b   Jokiel, B ^a   Pfeiffer, S ^a   Tiel Wilck, K ^a   Schmitz, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Adverse events; Antiepileptic drugs; Epilepsy; Reversibility; Vigabatrin; Visual Field Constriction

Indexed keywords

VIGABATRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; HUMAN; MALE; OPHTHALMOLOGY; PERIMETRY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VISUAL FIELD; VISUAL FIELD DEFECT;

ADULT; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIMETRY; RECOVERY OF FUNCTION; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 0036041558     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-002-0789-y     Document Type: Article

References (18)

1. Severe persistent visual field constriction associated with vigabatrin
2. Demonstration eines neuen projektionskugelperimeters samt theoretischen und klinischen bemerkungen über perimetrie
3. Visual function loss from vigabatrin, effect of stopping the drug
4. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects
5. Visual field defects with vigabatrin: Epidemiology and therapeutic implications
6. Vigabatrin: Reversibility of severe concentric visual field defects after detection and drug withdrawal: A case report
7. Recovery of visual field constriction following discontinuation of vigabatrin
8. Visual dysfunction in patients receiving vigabatrin. Clinical and electrophysiologic findings
9. Vigabatrin as first Add-on treatment in carbamazepine-resistant epilepsy patients
10. Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina
11. Visual function is stable in patients who continue long-term vigabatrin therapy: Implications for clinical decision making
12. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin
13. Über die gesichtsfelduntersuchung am goldmann-perimeter
14. Concentration-related pharmacodynamic studies with vigabatrin and tiagabine in rat brain and eye
15. Visual field constriction: Accumulation of vigabatrin but not tiagabin in the retina
16. Reversibility of vigabatrin induced visual-field defect
17. Characteristics of a unique visual field defect attributed to Vigabatrin
18. Severe persistent visual field constriction associated with vigabatrin